Establishment Labs Hldgs Inc Stock Price, News & Analysis

Holzer & Holzer, LLC is investigating Establishment Labs Holdings Inc. (NASDAQ:ESTA) for potential compliance failures with federal securities laws. Following a report by Hindenburg Research, which alleged undisclosed conflicts of interest in key safety studies of Establishment Labs' breast implants, the company's stock price experienced a decline. The report claims significant pushback was received by a surgeon for publishing higher complication rates than those reported by the company. Shareholders who incurred losses are encouraged to contact Holzer & Holzer for potential legal recourse.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, has secured Hani Zeini for a multiyear advisory role as it prepares for its US market launch. Zeini, with over 30 years in aesthetics, previously founded Sientra. His expertise will drive the company's strategy to introduce innovative breast aesthetics solutions, including the Motiva Implant product suite. With 2.0 million implants distributed globally, Establishment Labs is on track to enhance its market presence.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported second-quarter revenues of $41.2 million, a 28.7% increase year-over-year, marking a new record. Adjusted for currency fluctuations, growth would have been 33.3%. Gross profit was 66.7% of revenue, slightly down from 67.1% in 2021. Operating expenses rose to $37.9 million, a 45% increase compared to the previous year. The company maintains its 2022 revenue guidance of $155 million to $165 million. Cash balance stood at $91.3 million as of June 30, 2022, bolstered by a new $225 million credit facility.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the completion of patient enrollment in the Motiva US IDE clinical study, which involved 827 patients across 32 centers in the US, Germany, and Sweden. The study aims to evaluate the safety and effectiveness of Motiva breast implants in various procedures. The company plans to file its PMA submission to the FDA in Q4 2023, building on this significant milestone, especially amid the challenges posed by the pandemic. The Motiva implants have been positively received in reconstructive surgery.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q2 2022 on August 8, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results. The company specializes in women's health, focusing on breast aesthetics and reconstruction, and has delivered over 2 million Motiva Implants since its launch in 2010. Their implants are known for advanced features that aim to enhance aesthetic and clinical outcomes.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that its CEO, Juan José Chacón-Quirós, and CFO, Raj Denhoy will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am Eastern Time. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Founded to enhance women's health, Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative products like Motiva Implants®, with 2 million units distributed globally since 2010.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported strong first-quarter 2022 results, with revenue of $38.5 million, a 26.8% year-over-year increase. Despite reaching a record high in sales, gross profit margin declined to 64.8% due to higher inventory reserves. Operating expenses surged 37.5% to $30.5 million, contributing to a net loss of $5.6 million, up from $2.1 million the previous year. The company maintains its revenue guidance of $155 million to $165 million for 2022, reflecting an ambitious growth outlook.